ARS Pharmaceuticals drops on abandoning DTC neffy marketing, Q2 EPS miss
· seekingalpha.com
ARS Pharma (SPRY) plunges after-hours as it drops neffy direct-to-consumer marketing, targets top prescribers, cuts SG&A, and updates 2027 cash-flow...
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...